-+ 0.00%
-+ 0.00%
-+ 0.00%

Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad

Barchart·10/29/2026 02:20:00
Listen to the news

Detailed efficacy and safety results from the pivotal phase 3 study demonstrate statistically significant serum urate reductions through 12 months

Pozdeutinurad is an investigational, once-daily, highly selective URAT1 inhibitor

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.